Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Snyder K, Hilliard D, Tanen M, Cilissen C, De Smet M, de Lepeleire I, Van Dyck K, Wang AQ, Zeng W, Davies MJ, Tanaka W, Holst JJ, Deacon CF, Gottesdiener KM, Wagner JA. Herman GA, et al. Among authors: de smet m, de lepeleire i. J Clin Endocrinol Metab. 2006 Nov;91(11):4612-9. doi: 10.1210/jc.2006-1009. Epub 2006 Aug 15. J Clin Endocrinol Metab. 2006. PMID: 16912128 Clinical Trial.
Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist.
Lai E, Wenning LA, Crumley TM, De Lepeleire I, Liu F, de Hoon JN, Van Hecken A, Depré M, Hilliard D, Greenberg H, O'Neill G, Metters K, Gottesdiener KG, Wagner JA. Lai E, et al. Among authors: de lepeleire i, de hoon jn. Clin Pharmacol Ther. 2008 Jun;83(6):840-7. doi: 10.1038/sj.clpt.6100345. Epub 2007 Sep 19. Clin Pharmacol Ther. 2008. PMID: 17882161 Clinical Trial.
Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.
Wenning LA, Petry AS, Kost JT, Jin B, Breidinger SA, DeLepeleire I, Carlini EJ, Young S, Rushmore T, Wagner F, Lunde NM, Bieberdorf F, Greenberg H, Stone JA, Wagner JA, Iwamoto M. Wenning LA, et al. Clin Pharmacol Ther. 2009 Jun;85(6):623-7. doi: 10.1038/clpt.2009.12. Epub 2009 Mar 11. Clin Pharmacol Ther. 2009. PMID: 19279563 Clinical Trial.
Effect of diltiazem, a moderate CYP3A inhibitor, on the pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein inhibitor, in healthy subjects.
Garg A, Maes A, Corr C, Jin B, Wadhwa T, Handa N, Van Dyck K, De Lepeleire I, Shah J, Wagner JA, Krishna R. Garg A, et al. Among authors: de lepeleire i. J Clin Pharmacol. 2011 Mar;51(3):436-9. doi: 10.1177/0091270010368676. Epub 2010 Apr 23. J Clin Pharmacol. 2011. PMID: 20418508 Clinical Trial. No abstract available.
A comparison of the natriuretic and kaliuretic effects of cicletanine and hydrochlorothiazide in prehypertensive and hypertensive humans.
Wagner F, Malice MP, Wiegert E, McGrath HE, Gildea J, Mitta S, Van Dyck K, De Lepeleire I, Johnson-Levonas AO, Sisk CM, Fernandez R, Greenwalt DM, Beals C, Carey RM, Nunes I. Wagner F, et al. Among authors: de lepeleire i. J Hypertens. 2012 Apr;30(4):819-27. doi: 10.1097/HJH.0b013e32835022a8. J Hypertens. 2012. PMID: 22278145 Clinical Trial.
Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
Anderson MS, Gilmartin J, Cilissen C, De Lepeleire I, Van Bortel L, Dockendorf MF, Tetteh E, Ancona JK, Liu R, Guo Y, Wagner JA, Butterton JR. Anderson MS, et al. Among authors: de lepeleire i. Antivir Ther. 2015;20(4):397-405. doi: 10.3851/IMP2920. Epub 2014 Dec 3. Antivir Ther. 2015. PMID: 25470746 Clinical Trial.
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
Feng HP, Caro L, Fandozzi C, Chu X, Guo Z, Talaty J, Panebianco D, Dunnington K, Du L, Hanley WD, Fraser IP, Mitselos A, Denef JF, De Lepeleire I, de Hoon JN, Vandermeulen C, Marshall WL, Jumes P, Huang X, Martinho M, Valesky R, Butterton JR, Iwamoto M, Yeh WW. Feng HP, et al. Among authors: de lepeleire i. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02142-18. doi: 10.1128/AAC.02142-18. Print 2019 Apr. Antimicrob Agents Chemother. 2019. PMID: 30745392 Free PMC article. Clinical Trial.
Rhinovirus-16 induced temporal interferon responses in nasal epithelium links with viral clearance and symptoms.
Ravi A, Chang M, van de Pol M, Yang S, Aliprantis A, Thornton B, Carayannopoulos LN, Bautmans A, Robberechts M, De Lepeleire I, Singh D, Hohlfeld JM, Sterk PJ, Krug N, Lutter R; U-BIOPRED Study Group. Ravi A, et al. Among authors: de lepeleire i. Clin Exp Allergy. 2019 Dec;49(12):1587-1597. doi: 10.1111/cea.13481. Epub 2019 Oct 31. Clin Exp Allergy. 2019. PMID: 31400236 Free PMC article. Clinical Trial.
Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial.
Schürmann D, Rudd DJ, Zhang S, De Lepeleire I, Robberechts M, Friedman E, Keicher C, Hüser A, Hofmann J, Grobler JA, Stoch SA, Iwamoto M, Matthews RP. Schürmann D, et al. Among authors: de lepeleire i. Lancet HIV. 2020 Mar;7(3):e164-e172. doi: 10.1016/S2352-3018(19)30372-8. Epub 2020 Jan 3. Lancet HIV. 2020. PMID: 31911147 Clinical Trial.
77 results